Cardiac Adenylyl Cyclase and Phosphodiesterase Expression Profiles Vary by Age, Disease, and Chronic Phosphodiesterase Inhibitor Treatment

• Published in: Journal of cardiac failure Vol. 23; no. 1; pp. 72 - 80
• Main Authors: Nakano, Stephanie J., MD, Sucharov, Juliana, van Dusen, Robert, BS, Cecil, Mackenzie, Nunley, Karin, MS, Wickers, Sean, Karimpur-Fard, Anis, PhD, Stauffer, Brian L., MD, Miyamoto, Shelley D., MD, Sucharov, Carmen C., PhD
• Format: Journal Article
• Language: English
• Published: United States 01-01-2017
• Subjects: Adenylyl Cyclases - biosynthesis; Adenylyl Cyclases - genetics; Age Factors; Cardiovascular; Child; Child, Preschool; Female; Gene Expression Regulation; Heart Failure - drug therapy; Heart Failure - genetics; Heart Failure - metabolism; Humans; Male; Middle Aged; Myocardium - enzymology; Phosphodiesterase Inhibitors - therapeutic use; Phosphoric Diester Hydrolases - biosynthesis; Phosphoric Diester Hydrolases - genetics; Real-Time Polymerase Chain Reaction; RNA - genetics; phosphodiesterase; Adenylyl cyclase; single ventricle congenital heart disease; dilated cardiomyopathy
• ISSN: 1071-9164; 1532-8414
• DOI: 10.1016/j.cardfail.2016.07.429

Abstract Background Pediatric heart failure (HF) patients have a suboptimal response to traditional HF medications, although phosphodiesterase-3 inhibition (PDE3i) has been used with greater success than in the adult HF population. We hypothesized that molecular alterations specific to children with HF and HF etiology may affect response to treatment. Methods and Results Adenylyl cyclase (AC) and phosphodiesterase (PDE) isoforms were quantified by means of quantitative real-time polymerase chain reaction in explanted myocardium from adults with dilated cardiomyopathy (DCM), children with DCM, and children with single-ventricle congenital heart disease of right ventricular morphology (SRV). AC and PDE expression profiles were uniquely regulated in each subject group and demonstratde distinct changes in response to chronic PDE3i. There was unique up-regulation of AC5 in adult DCM with PDE3i (fold change 2.415; P  = .043), AC2 in pediatric DCM (fold change 2.396; P  = .0067), and PDE1C in pediatric SRV (fold change 1.836; P  = .032). Remarkably, PDE5A expression was consistently increased across all age and disease groups. Conclusions Unique regulation of AC and PDE isoforms supports a differential molecular adaptation to HF in children compared with adults, and may help identify mechanisms specific to the pathogenesis of pediatric HF. Greater understanding of these differences will help optimize medical therapies based on age and disease process.